- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Gain Therapeutics Announces Positive Phase 1 Results For GT-02287 In GBA1 Parkinson's Disease Trial | 1 | RTTNews | ||
| 24.04. | Gain Therapeutics, Inc.: Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease | 38 | GlobeNewswire (Europe) | BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 08.04. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.04. | Gain Therapeutics names Gene Mack as CFO | 2 | Seeking Alpha | ||
| 08.04. | Gain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer | 101 | GlobeNewswire (Europe) | BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 01.04. | Gain Therapeutics gets new chief medical officer | 2 | Seeking Alpha | ||
| 01.04. | Gain Therapeutics, Inc.: Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer | 176 | GlobeNewswire (Europe) | BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 26.03. | Gain Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.03. | Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M | 1 | Seeking Alpha | ||
| 26.03. | Gain Therapeutics: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 26.03. | Gain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 26.03. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update | 66 | GlobeNewswire (Europe) | BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 15.03. | Gain Therapeutics, Inc.: Gain Therapeutics to Present at Public Ventures Discovery Day | 3 | GlobeNewswire (USA) | ||
| 05.03. | Gain Therapeutics, Inc.: Gain Therapeutics Presents Data at the AD/PD 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease | 4 | GlobeNewswire (USA) | ||
| 05.03. | EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease | 3 | Benzinga.com | ||
| 27.02. | Gain Therapeutics, Inc.: Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease | 69 | GlobeNewswire (Europe) | BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 22.02. | Gain Therapeutics falls after CFO resigns | 1 | Reuters | ||
| 22.02. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.02. | Gain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight | 1.155 | GlobeNewswire (Europe) | BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -1,27 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,050 | +28,68 % | EQS-News: Defence Therapeutics Inc.: Pankreaskrebs: Erfolgreicher Test zur Bekämpfung von Pankreaskrebs mit dem ARM-002-Impfstoff von Defence | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,916 | +1,91 % | Impulse setzen - Cardiol Therapeutics, Evotec, Redcare Pharmacy Aktie | Für risikobewusste Anleger ist die Pharma- und Biotechsparte ein lukrativer Markt für Investitionen. Die Branche wächst seit Jahrzehnten und auch für die kommenden Jahre wird mit einem Wachstum von... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,858 | +1,89 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,900 | +5,34 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,705 | +4,38 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,070 | +3,88 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| CIDARA THERAPEUTICS | 12,470 | +12,14 % | Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 | SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,415 | -5,32 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,999 | +9,28 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,400 | +0,86 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | +0,17 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,020 | +3,09 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,170 | +3,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,400 | +0,75 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,34 % bei einem Aktienkurs von 2,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
